There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Vertex (VERX – Research Report) and AppLovin ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Most of the focus in generative AI has been on text-based interfaces used to generate text, images, and more. The next wave appears to be voice, and it’s ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

Below is a table showing the current thinking of the analysts that cover Vertex Pharmaceuticals, Inc.: ...

Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq ...

Three Florida Tech students are making a mechanical 'spy' manatee to covertly learn sea cows' deepest secrets.

Vertex Background Information (This description ... and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options ...

Vertex Pharmaceuticals is an innovative biotech ... That's why third-party payers have increasingly opted to cover them. Yet, even in the U.S., the percentage of CGM users trails the covered ...

It's worth mentioning that the Orum deal comes as Vertex has sued the US Government for failing to cover a fertility support programme for Casgevy, for example freezing and storing eggs.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.